233 related articles for article (PubMed ID: 9134172)
1. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients.
Jantunen E; Ruutu P; Niskanen L; Volin L; Parkkali T; Koukila-Kähkölä P; Ruutu T
Bone Marrow Transplant; 1997 Apr; 19(8):801-8. PubMed ID: 9134172
[TBL] [Abstract][Full Text] [Related]
2. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
Hovi L; Saarinen-Pihkala UM; Vettenranta K; Saxen H
Bone Marrow Transplant; 2000 Nov; 26(9):999-1004. PubMed ID: 11100280
[TBL] [Abstract][Full Text] [Related]
3. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases.
Martino R; Nomdedéu J; Altés A; Sureda A; Brunet S; Martínez C; Domingo-Albós A
Bone Marrow Transplant; 1994 Mar; 13(3):265-9. PubMed ID: 8199569
[TBL] [Abstract][Full Text] [Related]
4. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
6. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
[TBL] [Abstract][Full Text] [Related]
7. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
9. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A.
Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A
Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746
[TBL] [Abstract][Full Text] [Related]
11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
[TBL] [Abstract][Full Text] [Related]
13. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.
Miyakoshi S; Kusumi E; Matsumura T; Hori A; Murashige N; Hamaki T; Yuji K; Uchida N; Masuoka K; Wake A; Kanda Y; Kami M; Tanaka Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 Jul; 13(7):771-7. PubMed ID: 17580255
[TBL] [Abstract][Full Text] [Related]
14. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
[TBL] [Abstract][Full Text] [Related]
15. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
16. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
17. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Jantunen E; Nihtinen A; Volin L; Juvonen E; Parkkali T; Ruutu T; Anttila VJ
Bone Marrow Transplant; 2004 Nov; 34(10):891-5. PubMed ID: 15517009
[TBL] [Abstract][Full Text] [Related]
18. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
[TBL] [Abstract][Full Text] [Related]
19. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation.
Spinelli S; Chiodi S; Costantini S; Van Lint MT; Raiola AM; Ravera GB; Bacigalupo A
Haematologica; 2003 Oct; 88(10):1163-8. PubMed ID: 14555313
[TBL] [Abstract][Full Text] [Related]
20. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]